Patents Issued in April 25, 2024
  • Publication number: 20240132861
    Abstract: Disclosed herein include methods and compositions for incorporating an effector gene into the genome of a cell. The method can comprise introducing into a cell a donor nucleic acid comprising a recognition site, a splice acceptor site, a self-cleaving peptide sequence, an effector gene, and an optional transcript stabilization element. The donor nucleic acid can be incorporated into the intron of a target gene differentially expressed in a unique cell type and/or in a cell during a unique cell state via non-homologous end joining (NHEJ)-dependent DNA repair. There are also provided, in some embodiments, methods and compositions for treating a disease or disorder in a subject.
    Type: Application
    Filed: June 11, 2023
    Publication date: April 25, 2024
    Inventors: Yuki Oka, Allan-Hermann Pool
  • Publication number: 20240132862
    Abstract: Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.
    Type: Application
    Filed: September 21, 2023
    Publication date: April 25, 2024
    Applicant: Duke University
    Inventors: James Jefferson Smith, Derek Jantz, Homme W. Hellinga
  • Publication number: 20240132863
    Abstract: The present disclosure provides a D1L2 enzyme lacking a proline-rich domain (PRD) and/or lacking the C-terminal Arg residue, which is efficiently produced in microbial expression systems such as Pichia pastoris, and has high activity for degrading chromatin at acidic pH. The present disclosure provides methods of the production and use of the D1L2 enzyme in therapy.
    Type: Application
    Filed: February 17, 2022
    Publication date: April 25, 2024
    Inventors: Tobias A. FUCHS, Angelene Prasanna
  • Publication number: 20240132864
    Abstract: The present invention relates to a process for the production of a filamentous fungus whole broth enzyme composition with low biomass formation and high protein yield, a genetically modified filamentous fungus cell for production of the whole broth enzyme composition, the use of such a genetically modified filamentous fungus cell for the production of the filamentous fungus whole broth enzyme composition with low biomass formation and high protein yield and a filamentous fungus whole broth enzyme composition produced by such a method.
    Type: Application
    Filed: December 13, 2021
    Publication date: April 25, 2024
    Inventors: Christian GAMAUF, Jörg CLAREN
  • Publication number: 20240132865
    Abstract: The present disclosure relates to a recombinant protein of beta-galactosidase-1 (GLB1) with a truncated C-terminus; a pharmaceutical composition for the treatment, prevention or amelioration of GM1 gangliosidosis or Morquio syndrome B, the pharmaceutical composition comprising the above protein; a method for treating, preventing or ameliorating GM1 gangliosidosis or Morquio syndrome B, the method comprising administering to a subject the above pharmaceutical composition; and a method of producing the above protein. In one embodiment of the present disclosure, the recombinant protein of GLB1 with a truncated C-terminus does not pose an issue of heterogeneous protein truncation, shows an equivalent enzymatic activity compared to a full-length GLB1 protein and increases GLB1 enzyme activity in a patient's blood. The present disclosure shows that the above protein may be used to treat, prevent or ameliorate GM1 gangliosidosis or Morphio syndrome B.
    Type: Application
    Filed: September 8, 2023
    Publication date: April 25, 2024
    Applicant: NOVEL PHARMA INC.
    Inventor: Dong Kyu JIN
  • Publication number: 20240132866
    Abstract: The present disclosure provides the sequence of a Paenibacillus polymyxa preproenzyme which is the precursor of a neutral protease, expression thereof in a transformed host organism, and methods for production of the neutral protease, by recombinant means. Further, use of the recombinantly produced neutral protease is disclosed in the field of cell biology, particularly for the purpose of tissue dissociation. The disclosure also includes blends with other proteases. Further disclosed are nucleotide sequences encoding the neutral protease.
    Type: Application
    Filed: November 22, 2022
    Publication date: April 25, 2024
    Inventors: Thomas Greiner-Stoeffele, Stefan Schoenert
  • Publication number: 20240132867
    Abstract: The disclosure provides compositions comprising novel adenosine base editors (e.g., ABE8) that have increased efficiency and methods of using these adenosine deaminase variants for editing a target sequence.
    Type: Application
    Filed: October 13, 2023
    Publication date: April 25, 2024
    Applicant: Beam Therapeutics Inc.
    Inventors: Nicole GAUDELLI, Michael PACKER, Ian SLAYMAKER, Yi YU, Bernd ZETSCHE, Jason Michael GEHRKE, Natalie PETROSSIAN, Angelica MESSANA, Yvonne ARATYN, Francine GREGOIRE, Genesis LUNG, Shaunna BERKOVITCH, David A. BORN, Seung-Joo LEE
  • Publication number: 20240132868
    Abstract: The invention features polynucleotides that encode bases editors having a heterologous intron for self-inactivation, compositions comprising such polynucleotides, and methods of inactivating a base editor encoded by such polynucleotides.
    Type: Application
    Filed: November 27, 2023
    Publication date: April 25, 2024
    Applicant: Beam Therapeutics Inc.
    Inventors: David BRYSON, Jack SULLIVAN
  • Publication number: 20240132869
    Abstract: Disclosed herein are compositions and methods for making and using improved carbonic anhydrases for novel, sustainable, and low energy CO2 waste gas scrubbing technologies that are also transformational carbon capture technologies. Embodiments of methods, systems and compositions disclosed herein include, but are not limited to, non-aqueous solvents, advanced membranes, sorbents, and cryogenic systems that significantly reduce the cost of CO2 capture from coal and natural gas-fired power plants and industrial facilities. Methods disclosed herein reduce the energy and cost required for CO2 separation and can be applied for both pre-combustion and post-combustion CO2 capture.
    Type: Application
    Filed: February 22, 2022
    Publication date: April 25, 2024
    Inventors: Min ZHANG, Vladimir Vladimirovich LUNIN, Hui WEI
  • Publication number: 20240132870
    Abstract: At this invention I presents sophisticated way to treat leukemia and sophisticated way to have births.
    Type: Application
    Filed: October 23, 2022
    Publication date: April 25, 2024
    Inventor: Menni Menashe Zinger
  • Publication number: 20240132871
    Abstract: The present invention is related to an insert for a device for treating cells, wherein said insert comprises electrodes for emitting electric pulses and has an electrical connection, wherein a treatment space is provided in said insert, wherein said treatment space can be penetrated by the electric pulses emitted by said electrodes and an electric field resulting therefrom. The present invention is also related to such a device and to a method performed with said device.
    Type: Application
    Filed: March 3, 2022
    Publication date: April 25, 2024
    Inventor: Leandro BUCHMANN
  • Publication number: 20240132872
    Abstract: Provided herein are methods and compositions for the capture of nucleic acids, for example by using a nucleic acid-guided nuclease-based system.
    Type: Application
    Filed: February 1, 2023
    Publication date: April 25, 2024
    Inventors: Stephane B. GOURGUECHON, Eric HARNESS, David SINCLAIR, Meredith L. CARPENTER
  • Publication number: 20240132873
    Abstract: h The present disclosure provides compositions, methods, and systems related to template-mediated genome editing and modification. In particular, the present disclosure provides novel genome modification technology involving site-specific chemical modification of a nucleotide to introduce a replication-blocking lesion. The compositions, methods, and systems described herein facilitate efficient site-specific genome modification of a DNA target, while minimizing the unintended edits and cellular toxicity associated with current genome editing approaches.
    Type: Application
    Filed: February 14, 2022
    Publication date: April 25, 2024
    Inventors: Chase Lawrence Beisel, Scott Patrick Collins
  • Publication number: 20240132874
    Abstract: The current invention provides a synthetic prokaryotic genome comprising 5 or fewer occurrences of one or more sense codons; and/or a synthetic prokaryotic genome derived from a parent genome, wherein the synthetic prokaryotic genome comprises less than 10%, 5%, 2%, 1%, 0.5%, 0.1% of the occurrences of one or more sense codons, relative to the parent genome; and/or a synthetic prokaryotic genome comprising 100 or more, 200 or more, or 1000 or more genes with no occurrences of one or more sense codons.
    Type: Application
    Filed: October 23, 2023
    Publication date: April 25, 2024
    Inventors: Julius FREDENS, Kaihang WANG, Daniel DE LA TORRE, Louise F. H. FUNKE, Wesley E. ROBERTSON, Jason W. CHIN
  • Publication number: 20240132875
    Abstract: Aspects of the present disclosure include methods of producing modified polypeptides and modified polypeptide-ribosome or polypeptide-mRNA complexes, and methods of screening polynucleotide and polypeptide libraries. The present disclosure also provides polypeptide libraries useful in screening for single molecule phenotypes. Also provided are kits useful for producing polypeptides capable of being modified using methods disclosed herein.
    Type: Application
    Filed: April 11, 2023
    Publication date: April 25, 2024
    Applicant: The Trustees of the California State University
    Inventor: Kambiz Hamadani
  • Publication number: 20240132876
    Abstract: The present invention pertains to: a self-priming and replicating hairpin adaptor for constructing an NGS (next generation sequencing) library; and a method for constructing an NGS library using the same. Specifically, the present invention pertains to: a self-priming and replicating hairpin adaptor for constructing an NGS library, the adaptor containing a long single-stranded first oligonucleotide that comprises a nucleotide sequence of SEQ ID NO: 4 and has a hairpin structure, and a short single-stranded second oligonucleotide that comprises a nucleotide sequence of SEQ ID NO: 5; a method for constructing an NGS library using said adaptor; and an NGS library construction kit including said adaptor.
    Type: Application
    Filed: September 22, 2020
    Publication date: April 25, 2024
    Applicant: Korea University Research and Business Foundation
    Inventors: Cheul Hee JUNG, Seo Young KIM, Jun Y SHIN
  • Publication number: 20240132877
    Abstract: This application provides improved methods of genome editing. The genome editing systems described herein comprise a RNA-guided nuclease molecule and a Repair-Modulating Enzyme Molecule (RMEM).
    Type: Application
    Filed: February 1, 2023
    Publication date: April 25, 2024
    Inventors: Cecilia Cotta-Ramusino, Anne Helen Bothmer
  • Publication number: 20240132878
    Abstract: Diagnostic devices and methods are provided for screening for a disease condition, including a cancer condition or a mendelian disease. The diagnostic devices allow for in vivo contact of cell-free nucleic acids or circulating tumor cells. The diagnostic device has a needle with a body and a detection reaction module attached to the body.
    Type: Application
    Filed: February 22, 2023
    Publication date: April 25, 2024
    Applicant: GRAIL, LLC
    Inventor: M. Cyrus MAHER
  • Publication number: 20240132879
    Abstract: Provided herein are inorganic nucleic acid supramolecular structures and methods for making them. In certain aspects, the construct includes a structured nucleic acid polymer micelle, which micelle includes a structured nucleic acid template; one or more functional moieties attached to the template; and polymers that interact with nucleic acid present in the template to form the structured nucleic acid polymer micelle; and an inorganic shell surrounding the structured nucleic acid template, in which the one or more functional moieties extend outside the structured nucleic acid polymer micelle and the inorganic shell to maintain functionality.
    Type: Application
    Filed: June 28, 2023
    Publication date: April 25, 2024
    Inventors: Nayan Agarwal, Ashwin Gopinath, Emily Wu
  • Publication number: 20240132880
    Abstract: The present disclosure provides nucleic acid constructs and cell compositions for transcriptionally modifying a bacterial population within the gastrointestinal tract of a subject, and methods of use thereof.
    Type: Application
    Filed: October 19, 2023
    Publication date: April 25, 2024
    Inventor: Corey J. Wilson
  • Publication number: 20240132881
    Abstract: RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-3010 and compositions, methods, and uses thereof.
    Type: Application
    Filed: October 24, 2023
    Publication date: April 25, 2024
    Applicant: EmendoBio, Inc.
    Inventors: Lior Izhar, David Baram, Joseph Georgeson, Michal Golan-Mashiach, Asael Herman, Rafi Emmanuel
  • Publication number: 20240132882
    Abstract: Programmable guide RNAs (gRNAs) play a central role in the CRISPR revolution sweeping biology and medicine by directing the function of a Cas protein effector to a target gene of choice. To achieve programmable control over regulatory scope, the activity of a conditional guide RNA (cgRNA) depends on the presence or absence of an RNA trigger, allowing for cell-selective regulation of CRISPR/Cas function. Unlike a standard gRNA, a cgRNA is programmable at multiple levels, with the target-binding sequence controlling the target of Cas activity (edit, silence, induce, or bind a gene of choice) and the triggerbinding sequence controlling the scope of Cas activity. cgRNA mechanisms that are allosteric allow for independent design of the target and trigger sequences, providing the flexibility to select the regulatory target and scope independently.
    Type: Application
    Filed: December 12, 2023
    Publication date: April 25, 2024
    Inventors: Lisa Hochrein, Mikhail H. Hanewich-Hollatz, Zhewei Chen, Heyun Li, Shashank Gandhi, Marianne Bronner, Niles A. Pierce
  • Publication number: 20240132883
    Abstract: Disclosed are methods of RNA-triggered protein cleavage by the CRISPR Cas7-11-Csx29 complex. A guide RNA specifically hybridizes to a RNA target, and Csx29 cleaves Csx30 when Cas7-11:Csx29 complex binds to the target RNA.
    Type: Application
    Filed: August 15, 2023
    Publication date: April 25, 2024
    Inventors: Omar Abudayyeh, Jonathan Gootenberg, Hiroshi Nishimasu, Kazuki Kato, Cian Schmitt-Ulms, Kaiyi Jiang
  • Publication number: 20240132884
    Abstract: The present invention relates to compositions and methods for increasing the rate of site specific insertion of a donor DNA sequence to the genome. More specifically, the method introduces a donor DNA template containing at least one transcription factor binding site to a cell in order to favor specific insertion of a donor template sequence at a target site by homology directed repair (HDR).
    Type: Application
    Filed: September 27, 2023
    Publication date: April 25, 2024
    Applicant: EmendoBio Inc.
    Inventors: David Baram, Lior Izhar, Rafi Emmanuel
  • Publication number: 20240132885
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.
    Type: Application
    Filed: December 2, 2022
    Publication date: April 25, 2024
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
  • Publication number: 20240132886
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component 9 (C9) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a C9 gene and to methods of preventing and treating a C9-associated disorder, e.g., paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Type: Application
    Filed: June 29, 2023
    Publication date: April 25, 2024
    Inventors: Elane Fishilevich, Anna Borodovsky, Jeffrey Zuber
  • Publication number: 20240132887
    Abstract: Disclosed herein are, inter alia, inhibitors of protein arginine methyltransferase 9 and pharmaceutical compositions thereof, and methods comprising the use of protein arginine methyltransferase 9 inhibitors for the treatment of a protein arginine methyltransferase 9-modulated disease or disorder, such as a hematological cancer.
    Type: Application
    Filed: October 6, 2023
    Publication date: April 25, 2024
    Applicants: City of Hope, Western University of Health Sciences
    Inventors: Ling Li, Haojie Dong, Lei Zhang, Xin He, Yun Lyna Luo, Yi-Chun Lin
  • Publication number: 20240132888
    Abstract: Novel oligonucleotides that enhance silencing of the expression of a gene containing a single nucleotide polymorphism (SNP) relative to the expression of the corresponding wild-type gene are provided. Methods of using novel oligonucleotides that enhance silencing of the expression of a gene containing a SNP relative to the expression of the corresponding wild-type gene are provided.
    Type: Application
    Filed: August 9, 2023
    Publication date: April 25, 2024
    Inventors: Anastasia Khvorova, Julia Alterman, Faith Conroy, Edith Pfister, Neil Aronin, Ken Yamada
  • Publication number: 20240132889
    Abstract: Described are compounds and methods useful for the treatment and investigation of Friedreich's Ataxia.
    Type: Application
    Filed: September 19, 2023
    Publication date: April 25, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: David COREY, Liande LI
  • Publication number: 20240132890
    Abstract: The invention relates to nucleic acid molecules for pseudouridylation of a target uridine in a target RNA in a mammalian cell, wherein the nucleic acid molecule comprises a guide region capable of forming a partially double stranded nucleic acid complex with the target RNA comprising the target uridine, wherein the partially double stranded nucleic acid complex is capable of engaging a mammalian pseudouridylation enzyme, wherein the guide region assists in positioning the target uridine in the partially double stranded nucleic acid complex for it to be converted to a pseudouridine by the mammalian pseudouridylation enzyme.
    Type: Application
    Filed: September 27, 2023
    Publication date: April 25, 2024
    Applicants: University of Rochester, ProQR Therapeutics II B.V.
    Inventors: Bart KLEIN, Janne Juha TURUNEN, Lenka VAN SINT FIET, Pedro Duarte Morais Fernandes Arantes DA SILVA, Julien Auguste Germain BOUDET, Yi-Tao YU, Hironori ADACHI, Meemanage De ZOYSA
  • Publication number: 20240132891
    Abstract: MicroRNAs, or mimics thereof, for treating a subject suffering from nervous system dysfunction are described. Pharmaceutical compositions, viral vectors or viral particles, and nanoparticles comprising these microRNAs, or mimics thereof, are described. Methods of using these microRNAs, or mimics thereof, pharmaceutical compositions comprising the microRNAs, viral vectors, or nanoparticles are also described herein. These compositions and methods of use will provide novel therapies for patients suffering nervous system dysfunction, including but not limited to alpha-synucleinopathies and SCI.
    Type: Application
    Filed: October 9, 2023
    Publication date: April 25, 2024
    Applicant: Rutgers, The State University of New Jersey
    Inventors: M. Maral Mouradian, Eunsung Junn
  • Publication number: 20240132892
    Abstract: This disclosure relates to novel C9ORF72 targeting sequences. Novel oligonucleotides for the treatment of neurodegenerative diseases are also provided.
    Type: Application
    Filed: June 9, 2023
    Publication date: April 25, 2024
    Inventors: Anastasia Khvorova, Bruno Miguel da Cruz Godinho, James W. Gilbert
  • Publication number: 20240132893
    Abstract: A method of inhibiting the function of myostatin is provided. An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target sequence in exon 3 of the myostatin gene and is capable of allowing the expression of a splicing variant of myostatin. A pharmaceutical drug, a food, a feed, an agent for promoting myocyte proliferation and/or hypertrophy, an agent for increasing muscle mass and/or suppressing muscle weakness, an agent for switching the splicing of the myostatin gene from production of myostatin to production of a splicing variant thereof, an agent for decreasing myostatin signaling, and an anticancer agent, each of which comprises the above antisense oligonucleotide or a salt or a solvate thereof.
    Type: Application
    Filed: February 21, 2022
    Publication date: April 25, 2024
    Applicant: KNC LABORATORIES CO., LTD.
    Inventors: Masafumi MATSUO, Kazuhiro MAETA
  • Publication number: 20240132894
    Abstract: Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.
    Type: Application
    Filed: September 29, 2022
    Publication date: April 25, 2024
    Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Maria David Frank-Kamenetsky, Luciano Henrique Apponi, Young Jin Cho
  • Publication number: 20240132895
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a GSK3? gene, as well as methods of inhibiting expression of a GSK3? gene and methods of treating subjects having a GSK3? associated neurodegenerative disease or disorder, e.g., Fragile X Syndrome, using such dsRNAi agents and compositions.
    Type: Application
    Filed: September 7, 2023
    Publication date: April 25, 2024
    Inventors: William Cantley, Jeffrey Zuber, Adam Castoreno, Charalambos Kaittanis
  • Publication number: 20240132896
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Factor XII (F12) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an F12 gene and to methods of preventing and treating an F12-associated disorder, e.g., heredity angioedema (HAE), prekallikrein deficiency, malignant essential hypertension, hypertension, end stage renal disease, Fletcher Factor Deficiency, thromboembolic disease, inflammatory disease, or Alzheimer's Disease.
    Type: Application
    Filed: November 13, 2023
    Publication date: April 25, 2024
    Inventors: Karyn Schmidt, Mark K. Schlegel, Adam Castoreno
  • Publication number: 20240132897
    Abstract: The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 25, 2024
    Inventors: François GIULIANO, Alberto EPSTEIN, Olivier LE COZ, Alejandro ARANDA
  • Publication number: 20240132898
    Abstract: The invention provides a method for producing a plant cell modified at a targeted site of a double-stranded DNA, including (i) a step of providing a plant cell comprising the double-stranded DNA of interest, (ii) a step of providing a complex in which a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in the double-stranded DNA and a DNA glycosylase with sufficiently low reactivity with the double-stranded DNA are bound, (iii) a step of placing the complex in a condition under which the plant cell is transfected, (iv) a step of placing the transfected plant cell in a condition that induces modification of the targeted site, without cleaving at least one strand of the double-stranded DNA in the targeted site, and (v) a step of selecting a cell into which the complex has been introduced and/or a cell into which the modification has been introduced.
    Type: Application
    Filed: February 25, 2022
    Publication date: April 25, 2024
    Applicant: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
    Inventors: Keiji NISHIDA, Zenpei SHIMATANI, Ushio FUJIKURA
  • Publication number: 20240132899
    Abstract: The present disclosure is generally directed to gene editing in plant chloroplast and plant mitochondrial double-stranded DNA. Disclosed herein are cytosine base editors tailored for chloroplast and mitochondrial genomes in plants using plant-specific chloroplast and mitochondrial targeting peptides, a TALE, and a DNA deaminase. The systems of the present disclosure include DNA vectors and protocols to use them for gene editing in plants.
    Type: Application
    Filed: February 17, 2022
    Publication date: April 25, 2024
    Inventors: Bing Yang, Sinian Char, Riqing LI
  • Publication number: 20240132900
    Abstract: Disclosed are method and vectors for the application of POLQ in creating T-DNA free gene editing in plants. The method of simultaneous silencing of POLQ during CRISP/CAS9 gene editing increased the T-DNA free gene edited TO tobacco seedlings ratio. The method impacts the application of CRISPR gene editing technology in vegetatively propagated crops such as fruit trees by preventing the introduction of foreign DNA during gene editing.
    Type: Application
    Filed: February 24, 2023
    Publication date: April 25, 2024
    Inventors: Heqiang HUO, Guiluan WANG
  • Publication number: 20240132901
    Abstract: The present disclosure relates to tobacco plants, plant parts, seeds, compositions, and methods related to modulating the expression of novel genes in tobacco to regulate alkaloid levels.
    Type: Application
    Filed: August 3, 2023
    Publication date: April 25, 2024
    Applicant: ALTRIA CLIENT SERVICES LLC
    Inventors: Chengalrayan KUDITHIPUDI, Rajanikanth GOVINDARAJULU, Raja S. PAYYAVULA
  • Publication number: 20240132902
    Abstract: The present disclosure provides compositions and methods for producing transgenic plants and other organisms that exhibit increased production of mogroside compounds, in particular mogroside V, and the mogroside compounds, plants and plant parts so produced.
    Type: Application
    Filed: September 18, 2023
    Publication date: April 25, 2024
    Inventors: Tengfang Huang, Jack Q. Wilkinson, Anna Matthiadis, Devarshi Selote, Matthew Kilgore, Matthew DiLeo, Fayaz Khazi, Kevin Potter, Daniel Stauffer, Todd Rands
  • Publication number: 20240132903
    Abstract: The present disclosure provides composition, systems, devices and methods for plant-based production of non-plant proteins through the use of heterologous genes for the expression of said non-plant proteins. Non-plant proteins can include, but are not limited to, mammalian proteins, cytokines, or growth factors.
    Type: Application
    Filed: June 29, 2023
    Publication date: April 25, 2024
    Inventor: France-Emmanuelle ADIL
  • Publication number: 20240132904
    Abstract: The present invention relates to a method for producing recombinant human prethrombin-2 protein and having human ?-thrombin activity by the plant-based expression systems.
    Type: Application
    Filed: October 16, 2023
    Publication date: April 25, 2024
    Applicant: PROVIEW-MBD BIOTECH CO., LTD.
    Inventors: Yu-Chia CHANG, Jer-Cheng KUO, Ruey-Chih SU, Li-Kun HUANG, Ya-Yun LIAO, Ching-I LEE, Shao-Kang HUNG
  • Publication number: 20240132905
    Abstract: The present disclosure provides use of sweetpotato IbSAP15 gene in regulating leaf shape and flower shape of sweetpotato. Compared with the control, Ipomoea batatas cv. Xuzishu 8, IbSAP15-overexpressing lines have more deeply incised blades, dehiscent corollas, and higher ornamental value. In the present disclosure, overexpression of the sweetpotato IbSAP15 gene in sweetpotato can deepen leaf incisions, make trumpet-shaped corollas dehiscent, and change leaf shape and flower shape of sweetpotato. The present disclosure is suitable for developing sweetpotato germplasms with different leaf shape and flower shape and promotes ornamental flowering/foliage sweetpotato breeding.
    Type: Application
    Filed: November 17, 2022
    Publication date: April 25, 2024
    Applicant: XUZHOU INSTITUTE OF AGRICULTURAL SCIENCES
    Inventors: Yaju LIU, Hao XIE, Qiang LI, Yungang ZHANG, Hui YAN, Meng KOU, Wei TANG, Xin WANG, Qiangqiang YANG, Xiaoxiao WANG, Ranqiu LI
  • Publication number: 20240132906
    Abstract: The present invention relates to a lettuce plant, with a modified LsKO2 and/or Ls20ox1-B gene, wherein the homozygous presence of said genes leads to a shade tolerant phenotype, the wild-type LsKO2 gene and the wild-type Ls20ox1-B gene can have a coding sequence having at least 70% sequence identity to SEQ ID NO.: 9 and SEQ ID NO.: 11, respectively. The modification involves replacement and/or deletion and/or insertion of nucleotides resulting in an absence of functional KO2 and/or GA20ox1-B protein or the modification results in the absence of the wild-type LsKO2 and/or Ls20ox1-B gene. The homozygous presence of one or both of the modified LsKO2 and Ls20ox1-B genes or the homozygous absence of one or both of the wild-type LsKO2 and/or Ls20ox1-B genes in the plant confers shade tolerance as compared to a plant with the wild-type LsKO2 and Ls20ox1-B gene and not showing shade tolerance.
    Type: Application
    Filed: October 23, 2023
    Publication date: April 25, 2024
    Inventors: Carolina Myluska CARO RIOS, Cornelis Maria Petrus VAN DUN
  • Publication number: 20240132907
    Abstract: The disclosure relates to a plant that is tolerant or resistant to species of Ca. Liberibacter. Specifically exemplified are citrus and solanaceous plants. Provided by the disclosure is a modified citrus or solanaceous plant that is resistant or tolerant to Sec-dependent effectors secreted by bacteria. Also provided by the disclosure are methods of modifying a plant genome plant to provide tolerance or resistance to species of Ca. Liberibacter. Still further provided by the disclosure are methods conferring a population of plants with tolerance or resistance to species of Ca. Liberibacter and screening that population for the plants that are tolerant or resistant to species of Ca. Liberibacter.
    Type: Application
    Filed: December 28, 2022
    Publication date: April 25, 2024
    Inventor: Nian WANG
  • Publication number: 20240132908
    Abstract: The disclosure relates to novel soybean plants and seeds with pest and pathogen resistance and related compositions. The disclosure further relates to use of the soybean plants and seeds in breeding, seed production, and commodity product production.
    Type: Application
    Filed: December 3, 2021
    Publication date: April 25, 2024
    Inventors: Frédéric Van Ex, Katalin Tóth
  • Publication number: 20240132909
    Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The pesticidal proteins find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran and nematode pest populations and for producing compositions with insecticidal activity.
    Type: Application
    Filed: October 25, 2023
    Publication date: April 25, 2024
    Applicant: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: JENNIFER KARA BARRY, JAMES J ENGLISH, KEVIN A. FENGLER, ZHENGLIN HOU, LU LIU, ERIC SCHEPERS, JEFFREY SOPA, INGRID UDRANSZKY
  • Publication number: 20240132910
    Abstract: The present invention provides methods, compositions, and kits for preparing and using adeno associated virus and baculovirus. The methods for producing adeno associated virus and baculovirus particles include using histidine rich peptides and other cationic peptides as transfection reagents. The adeno associated virus are pseudotyped with capsids, in particular for use in gene therapy and/or diagnostics. The baculovirus are also used to prepare adeno associated virus.
    Type: Application
    Filed: February 10, 2022
    Publication date: April 25, 2024
    Applicant: BioMarin Pharmaceutical Inc.
    Inventors: Irina PEREVOSHCHIKOVA, Baran ARSLAN, Julie GARDIN, Pauline BOURBON, Helai ARABSHAHI, Tomas CINEK, Shilpa SHROFF